Dr. Reddy's faces revenue slowdown post gRevlimid boost, but new investments and partnerships offer long-term growth ...

Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Labs ADR saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 16%.

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

Dr. Reddy's Laboratories Ltd. closed 9.17% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

Alvotech and Dr. Reddy's Laboratories Ltd., today announced that the companies have entered into a collaboration and license ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Dr Reddy's announced a strategic partnership with Alvotech to develop a biosimilar to Keytruda, a top-selling cancer therapy ...

Dr Reddy's shares soar 3.54% after Alvotech partnership for Keytruda biosimilar, enhancing global reach in cancer ...

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...